| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The primary target is HMG-CoA reductase. The (3S,5R) stereoisomer of pitavastatin is expected to have significantly reduced or no inhibitory activity against HMG-CoA reductase compared to the active form. Its primary utility is as a reference standard in chiral analytical methods.
|
|---|---|
| ln Vitro |
In vitro activity is evaluated for quality control purposes. The compound is used as a standard in chiral chromatographic methods (e.g., chiral HPLC) to separate and quantify the stereoisomers of pitavastatin. Its own inhibitory activity against HMG-CoA reductase is expected to be very low.
|
| ln Vivo |
In vivo activity is not a significant consideration for this impurity. In pharmacokinetic studies, the levels of stereoisomers might be monitored, but the (3S,5R) isomer is not administered for therapeutic purposes.
|
| Enzyme Assay |
The non-cellular assay involves its use as a reference standard in analytical chemistry. A chiral HPLC method is used to separate (3S,5R)-pitavastatin from other stereoisomers, ensuring the quality of the drug substance.
|
| Cell Assay |
Cell-based assays are not typically performed with this impurity. If needed, its effect on cholesterol synthesis in HepG2 cells could be assessed, but its potency would be expected to be very low.
|
| Animal Protocol |
In vivo animal experiments are not relevant for this impurity. It is used for analytical quality control, not for biological research.
|
| References |
| Molecular Formula |
C₂₅H₂₄FNO₄.₁/₂CA
|
|---|---|
| Molecular Weight |
440.49
|
| Exact Mass |
880.284
|
| CAS # |
254452-88-5
|
| Related CAS # |
(3S,5S)-Pitavastatin calcium;254452-92-1;(Z)-Pitavastatin calcium;1159588-21-2
|
| PubChem CID |
12132652
|
| Appearance |
White to light yellow solid
|
| LogP |
3.5
|
| tPSA |
90.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
31
|
| Complexity |
631
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[Ca+2].FC1C=CC(=CC=1)C1C2C=CC=CC=2N=C(C=1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C1CC1.FC1C=CC(=CC=1)C1C2C=CC=CC=2N=C(C=1/C=C/[C@@H](C[C@@H](CC(=O)[O-])O)O)C1CC1
|
| InChi Key |
VGYFMXBACGZSIL-JUFISIKESA-N
|
| InChi Code |
InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m0/s1
|
| Chemical Name |
(E,3S,5R)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
|
| Synonyms |
(3S,5R)Pitavastatin calcium (3S,5R) Pitavastatin calcium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~113.5 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2702 mL | 11.3510 mL | 22.7020 mL | |
| 5 mM | 0.4540 mL | 2.2702 mL | 4.5404 mL | |
| 10 mM | 0.2270 mL | 1.1351 mL | 2.2702 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
